Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Operational update #2 from Nel ASA in relation to COVID-19

(Oslo, 26 March 2020) Nel Hydrogen US, a subsidiary of Nel ASA (Nel, OSE:NEL) has been defined as “essential manufacturing business” by the state of Connecticut and the plant in Wallingford can therefore resume operations. Revenues and operations will still be negatively impacted by disruptions in the value chain and extraordinary health measures taken due to COVID-19.   “The safety and well-being of our employees and co-citizens are our top priority and we have implemented strict measures to ensure continued and safe operations. Due to parts of our business relates to national

Citycon Oyj weakens its prospects and withdraws its financial guidance due to uncertain market situation

CITYCON OYJ   Inside information   26 March 2020 at 09:50 hrsCitycon Oyj assesses that its prospects for 2020 have weakened and withdraws its guidance for 2020 issued on 6 February 2020. At this point, the company does not specify its direct operating profit, EPRA EPS or adjusted EPRA EPS forecast for this year in more detail due to the uncertain market situation. “Following the outbreak of the COVID-19 epidemic, the authority restrictions confirmed in our operating countries has substantially changed our business environment and the prospects for 2020 now look weaker than originally

Realfiction Holding AB announces its Year-End Report

The company announces that the Year-End Report for January – December 2019 is now available. The full report is attached as a separate document and can also be downloaded from the company’s website (www.realfiction.com). A printed copy can be ordered via investor@realfiction.com. Below is a brief summary of the Year-End Report.Important key figures: •     28% decline in total revenue Q4, 2019 compared to Q4, 2018 •     26% decline in gross profit in Q4, 2019 compared to Q4, 2018 •     2% increase (1 point) in gross profit margin in Q4, 2019 compared to Q4, 2018 •     Solvency

SOTKAMO SILVER RENEGOTIATE SECURED BOND AND STRENGTHEN CASH POSITION

Press release: Stockholm, March 26, 2020 08.45 CETSotkamo Silver AB’s wholly owned subsidiary Sotkamo Silver Oy has renegotiated the terms and conditions of its EUR 13,200,000 Senior Secured Fixed Rate Notes 2018 (ISIN:FI4000315379) (the "Notes"). A written voting procedure in accordance with the rules and conditions of the Notes on amendments has been completed today. As a result, the noteholders have decided to: 1. Release the company from the obligation of having one year interest of EUR 1,320,000 on a pledged account;   2. Postpone the company’s obligation to collect funds into

Realfiction updates its guidance and pauses its test launch of MaaS for Retail in Germany due to the coronavirus situation

Realfiction Holding AB (“Realfiction”) announces that the company has a strong financial position and expects to have the liquidity necessary to sustain all its business operations, including the development of ECHO, into 2021. However, due to the current uncertainty, the company can no longer be certain that it will reach breakeven for its sales activities in 2020 as previously stated, and the company will not provide any new financial guidance until the coronavirus situation stabilizes.Realfiction was able to strengthen its financial situation significantly in Q4 2019, with 14.4 MSEK in

Scandion Oncology CEO Newsletter (March 2020)

Dear Scandion Oncology shareholder, Scandion Oncology wants to thank you for your continued trust and confidence in us and our work as we work through these challenging times together, and we hope that you and your families are safe and healthy. With the widening spread of COVID-19 across the world, we wanted to provide you with the latest updates on our activities, and, just as important, emphasize our continued commitment to bringing our drugs to the many cancer patients with untreatable drug resistant cancer disease.Clinical Phase II colorectal cancer study with SCO-101 to continue as

airteam secures contract in connection with new underground line in Copenhagen

airteam has secured a major ventilation and cooling contract in connection with construction of a new underground line to Copenhagen’s Sydhavn district. The project includes installations at five stations and two crossings.airteam is carrying out the project for the contractor TUNN3L JV, a joint venture between the French company Vinci and the German Hochtief. The project is expected to be finished in 2024, with the start scheduled for 2021.  “This is an interesting project that will mean a lot for Copenhagen and its inhabitants for years to come. I’m proud that airteam has been chosen

Quest for the cure.  Newsletter 2020 – Issue 2; Business Update - Hamlet Pharma receives EU grant for €2.2M

Last month, members of the Hamlet Pharma Executive Team travelled to Brussels in order to make a formal presentation of its grant request, Alpha 1H – A Unique Bladder Cancer Therapeutic, Acting with Great Precision, to the European Commission, Horizon 2020 – Research and Innovation Framework Programme. This is an extremely competitive programme, where innovators and business from all industries and backgrounds from across Europe, fight for funding with which to drive their respective visions further.We are extremely pleased and proud to announce that Hamlet Pharma’s grant application not

Tele2’s Annual Report 2019

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) today published the Annual Report 2019, which is available at www.tele2.com.For more information, please contact:Joel Ibson, Head of Corporate Communications, Phone: +46 766 26 44 00Marcus Lindberg, Head of Investor Relations, Phone: +46 73 439 25 40This is information that Tele2 AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08:30 CET on 26 March 2020.Tele2’s vision is to be the smartest telco in the world, creating a society of unlimited

Tele2’s Sustainability Report 2019: Committed to lead in sustainability

Stockholm – Tele2 AB’s (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) has today published its Sustainability Report 2019 at www.tele2.com. The report highlights how sustainability has been an integral aspect throughout a very eventful and transitional 2019. As such, Tele2 is now set up to fulfill its promise to lead in sustainability.Key highlights from Tele2’s sustainability efforts 2019: · MSCI AAA-rating maintained, top 9 percent globally within telecommunication services industry. · 35th place in Equileap’s 2019 Gender Equality Global Ranking & Report, ranked second among all

DNB Markets - Verisec: Freja eID momentum building up...

… as Covid-19 is forcing organisations to work remotely, resulting in a spike in demand for secure digital processes. Still, we are concerned about delayed sales cycles for its legacy security products, hence we have cut our 2020–2022e sales forecasts by ~10%, which cuts our fair value to SEK80–120 (100–140).Potential Covid-19 implications should work both ways for Verisec in our view. On the negative side, the business model is dependent on volumes, which should come down in a worsening economic climate, while sales cycles are likely to be delayed. Still, we believe that demand for its

DNB Markets - IAR Systems: Insiders showing the way

While Covid-19 does not stop the increased security risks the IoT can present, nor developers’ need for the flexible design processes offered by RISC-V, we have cut our 2020–2022e EBIT forecasts by 19%. Still, as its legacy tools are system-critical for its OEM customers, we estimate its fair value at SEK150–230 (230–275) and note that the stock is trading at a P/E 2021e of 16x, a 40% discount to its historical average.Potential Covid-19 impacts. It is still early days, but we believe sales processes in H1 2020 are likely to be delayed, with procurement departments working from home. For

Avidly Plc considers arranging a rights issue

Avidly Plc considers arranging a rights issue. The Board of Directors of Avidly aims to amend its proposal to the General Meeting to be held on 1 April 2020 concerning the authorization to issue shares.   Avidly Plc, company release, 26 March 2020 at  9.20 EET  Possible rights issue The board of directors of Avidly Plc (the “Company”) has today resolved to commence preparations in order to strengthen the Company’s equity by share issue with pre-emptive subscription rights for Company’s shareholders. The maximum amount of capital to be raised by the share issue, would be EUR 2.

Welcome to the Annual General Meeting of Studsvik AB

Studsvik AB (publ), corporate identity number 556501-0997, gives notice to attend the Annual General Meeting to be held on Wednesday April 29, 2020 at 16.00 at the World Trade Center, Klarabergsviadukten 70/Kungsbron 1 in Stockholm. Registration for the Annual General Meeting starts at 15.00.Registration and notification of attendance Shareholders who wish to participate in the Annual General Meeting must · be registered in the share register kept by Euroclear Sweden AB by Thursday, April 23, 2020, and · give notification to the company by Thursday, April 23, 2020 at the latest.

VibroSense adds application for screening of diabetes feet

VibroSense Dynamics AB (VibroSense) adds a new application to its product VibroSense Meter® II, which provides support for Diabetes Foot Screening. The new application is a result of 5 years of clinical studies involving adult patients with type 1 diabetes and is expected to be available for commercial launch in the fall 2020.The screening function of VibroSense Meter® II within HAVS (vibration damage), was launched in the fall 2019 and is an application to detect early nerve damage in hands caused by vibrating tools. Research at Skåne University Hospital have shown that the method can also

Proposals of postponement of the formal resolution for the second dividend installment and unchanged Board fees

Stockholm, Sweden, March 26, 2020: Atlas Copco’s Annual General Meeting will take place on April 23, 2020. The Board’s previous assessment of the dividend capacity for 2019 remains intact and as a consequence also the communicated dividend proposal. However, due to the COVID-19 outbreak and the uncertainty it is creating, the Board proposes that the final decision of the planned second installment of the dividend will be addressed at an Extraordinary General Meeting when the effects can be better assessed. Also, the Nomination Committee proposes unchanged Board Fees.Atlas Copco has a robust

Director/PDMR Shareholding

26 March 2020 07:00 GMT   Transactions by Persons Discharging Managerial Responsibilities Disclosure under Article 19 of the EU Market Abuse Regulation   AstraZeneca PLC (the Company) announced that, on 24 March 2020, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Deferred Bonus Plan (AZDBP).   The AZDBP award was granted on 24 March 2017, following the deferral of a portion of each PDMR's annual bonus paid in respect of 2016

Final Results for the Year Ended 31 December 2019

26 March 2020   Independent Oil and Gas plc Final Audited Results for the Year Ended 31 December 2019   Independent Oil and Gas plc ("IOG" or "the Company"), (AIM: IOG.L), the development and production company focused on becoming a substantial UK gas producer, is pleased to announce its final audited results for the Year Ended 31 December 2019.   2019 Highlights   Corporate and Operational   · Farm-out of 50% of Core Project to CalEnergy Resources Limited (“CER”) with IOG retaining operatorship of all its assets · Acquisition of the onshore Thames

Lokelma approved in Japan for hyperkalaemia

26 March 2020 07:00 GMT   Lokelma approved in Japan for the treatment of hyperkalaemia   Patients in Japan will benefit from Lokelma's rapid and sustained potassium control   AstraZeneca's Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood).   The approval by Japan's Ministry of Health, Labour and Welfare was based on positive results from stand-alone studies in Japan and global clinical trial programmes. It was also supported by DIALIZE, a global trial for

Invitation to presentation of Essity’s Interim report for the first quarter 2020

Essity’s Interim report for the first quarter of 2020 will be published on April 23 at approximately 7:00 CET. In conjunction with publication, a telephone and web presentation will be held at 9:00 CET where President and CEO Magnus Groth will present and answer questions.Presentation:Date: Thursday April 23, 2020Time: 9:00 CETLink to Web presentation: https://essity.videosync.fi/2020-04-23-q1Telephone: +44 (0) 207 192 80 00, +1 631 510 74 95 or +46 (0) 8 506 921 80. Please call in well in advance of the start of the presentation. Indicate “Essity” or conference ID 6966854.

Alimak Group publishes Annual Report for 2019

Alimak Group’s Annual Report 2019, including the sustainability report, has been published in Swedish and English.The annual report is attached to this press release and is also available at https://www.alimakgroup.com/English/investor-relations/. The Annual Report will be printed in a limited edition and can be ordered from investor@alimakgroup.com.  Stockholm, 26 March 2020 Alimak Group AB For more information, please contact:Mathilda Eriksson, Investor Relations and Group Communications Manager, +46 8 402 14 41Tobias Lindquist, CFO, Phone +46 (0)8 402 14 40 This

Remedy Entertainment signs two multi-platform publishing deals

Remedy Entertainment Plc | Insider information 9:00 am (EET) 26 March 2020 Remedy Entertainment signs two multi-platform publishing deals Remedy Entertainment, developer of multiple “Game of the Year” award winner Control, has signed publishing agreements with a major publisher for the company’s next two unannounced video games. The agreements specify that the publisher will fully fund game development costs and that Remedy is entitled to a 50% share of the net revenue from the games’ sales. Remedy also retains the ownership of the games’ intellectual property. The first project is

LKAB publishes annual and sustainability report for 2019

LKAB’s annual and sustainability report is available in Swedish at lkab.com as of today.During 2019, LKAB achieved strong earnings as a result of stable production and favourable market conditions, despite lower delivery volumes. The annual and sustainability report describes how LKAB creates value, impacts in the value chain, as well as strategic priorities and investments in projects for the transition into a more sustainable industry. LKAB aims to be one of the most innovative, resource-efficient and responsible companies in the industry and sustainability is at the core of our

Magnolia Bostad repurchases bonds and announces its intention to carry out further repurchases

Magnolia Bostad announced today that repurchases have been made of secured bonds with a nominal value of SEK 41,4.The repurchase relates to secured bonds, ISIN: SE0008293823 (the secured bonds) issued by Magnolia Bostad AB (publ) with a nominal outstanding amount of SEK 450,000,000. The bonds have a floating rate corresponding to STIBOR 3m plus 6.25% and fall due in April 2020. The average purchase price for the bonds corresponds to 99,55 % of the nominal amount. After the repurchase, Magnolia Bostad's holding of the secured bonds amounts to a nominal value of SEK 61,2. ”Magnolia Bostad

There are no items matching the current filter
There are no more items matching the current filter
Back to top